Leukemia and Lymphoma

Investigators Document Muscle Loss During Immunochemotherapy for DLBCL

October 17th 2021, 2:10pm


Investigators in a retrospective study of patients with diffuse large B-cell lymphoma (DLBCL) sought to understand the correlation between muscle loss and immunochemotherapy.

Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care

October 13th 2021, 1:26am


On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.

Addressing Disparities in Cancer Care and Beyond: What Can Be Done Now?

October 12th 2021, 8:26pm


Conversations on CAR T: Study of Checkpoint Inhibitors After Transplant Bolsters Case for CAR T, Skarbnik Says

October 11th 2021, 11:16pm


Conversations on CAR T: UAB’s Mehta Discusses Opportunities and Challenges

October 11th 2021, 10:45pm


Elevated Risks of NHL, Lung Cancer Increase Mortality in Recipients of Organ Transplant

October 9th 2021, 2:00pm


People who receive organ transplants have an elevated risk of developing cancer, particularly lung cancer and non-Hodgkin lymphoma (NHL).

Dr Karen Winkfield on Taking Action to Address Disparities in Cancer

October 7th 2021, 11:47pm


There is a lot of evidence on the disparities in cancer care, but less on how to take those findings and turn them into actionable items to address the problem, said Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance.

Review Outlines Progress on GE-Based Biomarkers for CML

October 7th 2021, 4:00pm


A recently published review outlines progress made in discovering biomarkers for chronic myeloid leukemia (CML).

Patient Characteristics Impact Effectiveness of TKIs in CML and AEs Experienced

October 1st 2021, 1:15pm


Dosing from pivotal phase 3 trials of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is not optimal for real-world patients who experience different efficacy and adverse events (AEs).

Second-Generation BTK Inhibitors Seek to Build Off Ibrutinib Success in CLL

September 29th 2021, 6:00pm


These second-generation inhibitors include acalabrutinib, zanubrutinib, and tirabrutinib, and researchers hope they can overcome the off-target toxicity and treatment resistance that can be experienced with ibrutinib.